Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

John Roboz, Shyamala C. Navada, MD, Sool Yeon Cho, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2018-99-115169

Published: 2018

Journal Articles

A Striking Reduction of Monoclonal Protein in a Patient with Concurrent Plasma Cell Dyscrasia and CMML-2, after Treatment with Rigosertib (01910.Na)

Jamile M. Shammo, MD, Agne Paner, MD, MV Ramana Reddy, PhD, Rachel L Mitchell, MD, Parameswaran Venugopal, MD

Blood (2015) 126 (23): 5362.

https://doi.org/10.1182/blood.V126.23.5362.5362

Published: 2015

Journal Articles

Rigosertib Blocks RAS Signaling By Acting As a Small Molecule RAS Mimetic That Binds to the RAS-Binding Domains of RAS Effector Proteins

E. Premkumar Reddy, PhD, Sai Krishna Divakar, PhD, Rodrigo Vasquez-Del Carpio, PhD, Kaushik Dutta, PhD, Stacey J Baker, PhD, Ramana Reddy, PhD, Aneel K Aggarwal, PhD

Blood (2014) 124 (21): 5616.

https://doi.org/10.1182/blood.V124.21.5616.5616

Published: 2014

Journal Articles

Efficacy Of The Polo-Like Kinase Inhibitor, Rigosertib Alone Or In Combination With ABL Tyrosine Kinase Inhibitor Against BCR-ABL-Positive Leukemia Cells

Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD, Toshihiko Kitahara, MD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 3985.

https://doi.org/10.1182/blood.V122.21.3985.3985

Published: 2013

Journal Articles

A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib),

Alice C Fan, MD, Liwen Xu, PhD, Kunju J Sridhar, PhD, Mai Tran, Prajna Banerjee, PhD, John P. Renschler, Radha Tripuraneni, MD, Francois Wilhelm, MD, PhD., Peter L. Greenberg, MD, Dean W. Felsher, MD, PhD

Blood (2011) 118 (21): 3808.

https://doi.org/10.1182/blood.V118.21.3808.3808

Published: 2011

Journal Articles

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Lewis R Silverman, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Vesna Najfeld, PhD, Takao Ohnuma, MD, Francois Wilhelm, MD, PhD., E. Premkumar Reddy, Ph.D., James F. Holland, MD

Blood (2010) 116 (21): 2944.

https://doi.org/10.1182/blood.V116.21.2944.2944

Published: 2010

Journal Articles

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

Mahesh Seetharam, MD, Mai Tran, Alice C. Fan, MD, Liwen Xu, PhD, John P. Renschler, Dean W. Felsher, MD, PhD, Kunju Sridhar, PhD, Francois Wilhelm, MD, PhD., Peter L. Greenberg, MD

Blood (2010) 116 (21): 4010.

https://doi.org/10.1182/blood.V116.21.4010.4010

Published: 2010

Journal Articles

ON 01910.Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size.

Elaine M Sloand, MD, Matthew J. Olnes, MD, PhD, Naomi Galili, PhD, Aarthi Shenoy, MD, Loretta Pfannes, Francois Wilhelm, MD, Ph.D, Barbara Weinstein, Phillip Scheinberg, MD, Jerome E. Groopman, MD, Azra Raza

Blood (2009) 114 (22): 120.

https://doi.org/10.1182/blood.V114.22.120.120

Published: 2009

Journal Articles

Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.

Lewis R. Silverman, MD, Rosalie Odchimar-Reissig, Shyamala C. Navada, MD, Takao Ohnuma, MD, Vesna Najfeld, Ph.D., Francois Wilhelm, MD, Ph.D, E. Premkumar Reddy, PhD, James F Holland

Blood (2009) 114 (22): 4839.

https://doi.org/10.1182/blood.V114.22.4839.4839

Published: 2009

Journal Articles

The PI3K Inhibitor ON 01910.Na Inhibits Critical Survival Pathways and Induces Apoptosis in CLL Cells through Induction of NOXA and BIM.

Patricia Perez Galan, PhD, Colby M Chapman, Federica Gibellini, PhD, Poching Liu, PhD, Nalini Raghavachari, PhD, Mark Roschewski, MD, Adrian Wiestner, MD, PhD

Blood (2009) 114 (22): 412.

https://doi.org/10.1182/blood.V114.22.412.412

Published: 2009

Journal Articles

Suppression of Cyclin D 1 (CD1) by on 01910.Na Is Associated with Decreased Survival or Trisomy 8 Myelodysplastic Bone Marrow: A Potential Targetted Therapy for Trisomy 8 MDS.

Aarthi Shenoy, MD, Loretta Pfannes, Francois Wilhelm, MD, Ph.D, Manoj Maniar, Ph.D, Neal Young, MD, Elaine M Sloand, MD

Blood (2008) 112 (11): 1651.

https://doi.org/10.1182/blood.V112.11.1651.1651

Published: 2008

Journal Articles

RGD-Substituted High Molecular Weight Hyper-Branched Polyglycerols (HPG) Are Effective Platelet Inhibitors.

Jerry G. Zhang, BSc, Oren Krajden, B.Sc., Rajesh K. Kainthan, Ph.D., Jayachandran N. Kizhakkedathu, Ph.D., Maria I.C. Gyongyossy-Issa, Ph.D

Blood (2007) 110 (11): 925.

https://doi.org/10.1182/blood.V110.11.925.925

Published: 2007

Journal Articles

Suppression of Cyclin D1 by on 01910.Na Is Associated with Decreased Survival of Trisomy 8 Myelodyplastic Bone Marrow Progenitors: A Potential Targetted Therapy.

Elaine M. Sloand, MD, Loretta Pfannes, Ramana Reddy, PhD, Premkumar Reddy, PhD, Jerome S. Groopman, MD, Neal S. Young, MD

Blood (2007) 110 (11): 822.

https://doi.org/10.1182/blood.V110.11.822.822

Published: 2007

Journal Articles

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

Christopher J. Kirk, PhD, Monette A. Aujay, B.S., Mark Ho, B.S., Jing Jiang, B.S., Guy J. Laidig, Ph.D., Evan R. Lewis, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Tina M. Woo, B.S., Congcong M. Sun, M.S., Catherine Sylvain, Ph.D., Jinfu Yang, Ph.D., Han-jie Zhou, Ph.D., Mark K. Bennett, Ph.D.

Blood (2006) 108 (11): 3581.

https://doi.org/10.1182/blood.V108.11.3581.3581

Published: 2006

Journal Articles

Evaluation of Novel Cell Cycle Inhibitors in Mantle Cell Lymphoma.

In-Woo Park, PhD, M.V. Ramana Reddy, Ph.D., E. Premkumar Reddy, Ph.D., Jerome E. Groopman, M.D.

Blood (2006) 108 (11): 4748.

https://doi.org/10.1182/blood.V108.11.4748.4748

Published: 2006

Journal Articles

Sulfur- and Selenium-Containing Compounds Derived from Natural and Synthetic Sources in Angiogenesis Modulation.

Shaker A. Mousa, PhD, MBA, FACC, FACB, Seema Mohamed, MS, Laura O’Connor, BS, Eric Block, PhD

Blood (2004) 104 (11): 3924.

https://doi.org/10.1182/blood.V104.11.3924.3924

Published: 2004

NARROW

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

A Striking Reduction of Monoclonal Protein in a Patient with Concurrent Plasma Cell Dyscrasia and CMML-2, after Treatment with Rigosertib (01910.Na)

Rigosertib Blocks RAS Signaling By Acting As a Small Molecule RAS Mimetic That Binds to the RAS-Binding Domains of RAS Effector Proteins

Efficacy Of The Polo-Like Kinase Inhibitor, Rigosertib Alone Or In Combination With ABL Tyrosine Kinase Inhibitor Against BCR-ABL-Positive Leukemia Cells

A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib),

Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study

Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na

ON 01910.Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size.

Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.

The PI3K Inhibitor ON 01910.Na Inhibits Critical Survival Pathways and Induces Apoptosis in CLL Cells through Induction of NOXA and BIM.

Suppression of Cyclin D 1 (CD1) by on 01910.Na Is Associated with Decreased Survival or Trisomy 8 Myelodysplastic Bone Marrow: A Potential Targetted Therapy for Trisomy 8 MDS.

RGD-Substituted High Molecular Weight Hyper-Branched Polyglycerols (HPG) Are Effective Platelet Inhibitors.

Suppression of Cyclin D1 by on 01910.Na Is Associated with Decreased Survival of Trisomy 8 Myelodyplastic Bone Marrow Progenitors: A Potential Targetted Therapy.

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

Evaluation of Novel Cell Cycle Inhibitors in Mantle Cell Lymphoma.

Sulfur- and Selenium-Containing Compounds Derived from Natural and Synthetic Sources in Angiogenesis Modulation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only